Armune BioScience

Armune BioScience

Armune BioScience

Developed the technology APIFINY®—a prostate-cancer-specific non-PSA blood test that may improve decision making when selecting men for prostate biopsies.
Founded
2005
Raised
$18.5M
Follow us
Alexa global traffic share
Twitter followers
Latest funding Show all
$5,000,000
Venture capital (Series A) - 2016
Grand Angels Venture Fund II
$9,710,000
Venture capital (Series A) - 2016
Maverick Capital
Team Size
10+
Employees
$5,000,000 Venture capital (Series A)
FinSMEs

Armune BioScience Closes $5M Series A Funding

Health Funding
$9,710,000 Venture capital (Series A)
grbj , Armune BioScience , sec

Medical diagnostics startup secures $9M in funding

Health Funding